StreetInsider.com News Articles

Form 424B5 Incannex Healthcare Inc.

Thu, 12 Mar 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260312/26153420.html

Form 424B5 Incannex Healthcare Inc.

Thu, 12 Mar 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260312/26153420.html

Form 8-K Incannex Healthcare Inc. For: Mar 12

Thu, 12 Mar 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260312/26149673.html

Form 8-K Incannex Healthcare Inc. For: Mar 12

Thu, 12 Mar 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260312/26149673.html

Form 8-K Incannex Healthcare Inc. For: Mar 11

Thu, 12 Mar 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260312/26149595.html

Form 8-K Incannex Healthcare Inc. For: Mar 11

Thu, 12 Mar 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260312/26149595.html

Incannex advances sleep apnea drug with new phase 2 study

Thu, 12 Mar 2026 08:00:14 -0400

Incannex Healthcare Inc. (NASDAQ: IXHL) announced plans for an additional Phase 2 study of its oral drug candidate IHL-42X for obstructive sleep apnea, following completion of its initial Phase 2 trial.

The company reported that its completed RePOSA Phase 2 trial showed 33.3% of patients in the low-dose group and 41.2% in the high-dose group achieved greater than 30% reduction in apnea-hypopnea index. The study also showed maximum reductions of 83% and 79% in the index for high and low dose groups respectively.

IHL-42X has received Fast Track Designation from the U.S. Food and Drug Administration, according to the company statement. The

Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes

Thu, 12 Mar 2026 08:00:00 -0400

Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 program

MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for the treatment of obstructive sleep apnea (OSA), following statistically significant outcomes across key endpoints in its completed Phase 2 program.

Importantly, IHL-42X has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), enabling more frequent interaction with the FDA

Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes

Thu, 12 Mar 2026 08:00:00 -0400

Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 program

Importantly, IHL-42X has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), enabling more frequent interaction with the FDA

Incannex Healthcare completes 1-for-30 reverse stock split

Wed, 25 Feb 2026 09:20:17 -0400

Incannex Healthcare Inc. (NASDAQ: IXHL) completed a 1-for-30 reverse stock split that took effect at 4:01 p.m. Eastern Time on February 26, 2026, according to a company statement. The pharmaceutical company's stock began trading on a post-split adjusted basis on February 27, 2026, under a new CUSIP number while maintaining its current ticker symbol.

The reverse split automatically converted every 30 existing shares of common stock into one share. Stockholders who would have received fractional shares due to holdings not evenly divisible by 30 will receive an additional fraction to round up to the next whole share. No cash payments will

Incannex Announces Reverse Stock Split

Wed, 25 Feb 2026 09:20:00 -0400

Incannex’s common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026

MELBOURNE, Australia and NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that the board of directors of the Company approved a 1-for-30 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on May 27, 2025. The Reverse Split will

Incannex Announces Reverse Stock Split

Wed, 25 Feb 2026 09:20:00 -0400

Incannex’s common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026

Form 8-K Incannex Healthcare Inc. For: Feb 24

Wed, 25 Feb 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260225/26055577.html

Form 8-K Incannex Healthcare Inc. For: Feb 24

Wed, 25 Feb 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260225/26055577.html

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026

Wed, 18 Feb 2026 18:35:00 -0400

Dallas, Texas--(Newsfile Corp. - February 18, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). Incannex continued to build the clinical and patient-reported evidence base for IHL-42X in obstructive sleep apnea (OSA), following full Phase 2 RePOSA data and exit-interview analyses. Both low and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index (AHI) versus placebo, with maximum AHI reductions of up to 83% in the high-dose arm. Exit interviews showed 57.6% of participants reported

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026

Wed, 18 Feb 2026 18:35:00 -0400

Form 10-Q Incannex Healthcare Inc. For: Dec 31

Fri, 13 Feb 2026 07:49:00 -0400

si-local-file:///var/storage/secattach/20260213/25995678.html

Form 10-Q Incannex Healthcare Inc. For: Dec 31

Fri, 13 Feb 2026 07:49:00 -0400

si-local-file:///var/storage/secattach/20260213/25995678.html

Form 8-K Incannex Healthcare Inc. For: Jan 29

Thu, 29 Jan 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260129/25912549.html

Form 8-K Incannex Healthcare Inc. For: Jan 29

Thu, 29 Jan 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260129/25912549.html

Incannex Healthcare adds three members to clinical advisory board

Thu, 29 Jan 2026 08:00:25 -0400

Incannex Healthcare Inc. (NASDAQ: IXHL) announced the appointment of three members to its Clinical Advisory Board to support development of its PSX-001 program. The company named Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD to the board.

The Clinical Advisory Board provides clinical and scientific guidance as the company advances PSX-001 into its next phase of clinical and regulatory development. PSX-001 is an oral synthetic psilocybin treatment approved for Phase 2 clinical development for generalized anxiety disorder.

Dr. Stein serves as Distinguished Professor of Psychiatry and Public Health at the University of California San Diego and is recognized

Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

Thu, 29 Jan 2026 08:00:00 -0400

Expands clinical expertise to support disciplined advancement of the PSX-001 program

MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board (“CAB”): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD.

The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens

Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

Thu, 29 Jan 2026 08:00:00 -0400

Expands clinical expertise to support disciplined advancement of the PSX-001 program

Incannex Healthcare forms clinical advisory board for PSX-001 program

Thu, 22 Jan 2026 08:00:21 -0400

Incannex Healthcare Inc. (NASDAQ: IXHL) announced the formation of a Clinical Advisory Board to support development of its PSX-001 program for generalized anxiety disorder. The biopharmaceutical company said the board will provide clinical and scientific guidance as PSX-001 advances to its next development phase.

The advisory board includes three psychiatry experts: Dr. C. Neill Epperson from University of Colorado School of Medicine, Dr. Charles B. Nemeroff from The University of Texas at Austin Dell Medical School, and Dr. Alan F. Schatzberg from Stanford University School of Medicine. The board will advise on clinical trial design, endpoint selection, regulatory engagement, and strategic

Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program

Thu, 22 Jan 2026 08:00:00 -0400

Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of development

MELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces the formation of a Clinical Advisory Board (CAB) to support the continued advancement of its PSX-001 development program in generalized anxiety disorder.

The newly established CAB has been formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The CAB gathers leading experts in psychiatry,